Stockscreener 앱 받기
1.91
1.06%
0.02
시간 외 거래:
1.91
전일 마감가:
$1.89
열려 있는:
$1.89
하루 거래량:
1.96M
Relative Volume:
0.39
시가총액:
$162.67M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-1.3741
EPS:
-1.39
순현금흐름:
$-46.54M
1주 성능:
-3.54%
1개월 성능:
-2.55%
6개월 성능:
+31.72%
1년 성능:
-5.45%
1일 변동 폭
$1.86
$1.94
1주일 범위
$1.86
$2.04
52주 변동 폭
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.91 | 160.97M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-09-11 | 개시 | Wells Fargo | Overweight |
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 11,180 Shares - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock - MarketBeat
Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Finviz
Milestone Pharmaceuticals announces U.S. availability of cardamyst - Yahoo Finance
Milestone’s PSVT treatment CARDAMYST now available in US pharmacies By Investing.com - Investing.com Canada
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies - TipRanks
Milestone Pharmaceuticals (MIST) Launches Cardamyst Nasal Spray in U.S. Market - GuruFocus
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewswire
Bull Run: Should I set a stop loss on Milestone Pharmaceuticals IncJuly 2025 Action & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug Fed Impact: Will Cohen Circle Acquisition Corp I outperform during market ralliesJuly 2025 Retail & Free Verified High Yield Trade Plans - baoquankhu1.vn
Insider Trends: Is Milestone Pharmaceuticals Inc undervalued by DCF analysisJuly 2025 Reactions & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for Milestone Pharmaceuticals Inc stockM&A Rumor & Growth Focused Investment Plans - baoquankhu1.vn
Earnings Miss: Is Milestone Pharmaceuticals Incs ROIC above industry averageJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
Aug Mood: Should I invest in Milestone Pharmaceuticals Inc before earningsCPI Data & Daily Profit Focused Screening - baoquankhu1.vn
US Stocks Recap: Is Milestone Pharmaceuticals Inc vulnerable to short sellers2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
Swing Trade: How does Milestone Pharmaceuticals Inc compare to its peersWeekly Trend Summary & Long-Term Growth Plans - baoquankhu1.vn
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Institutional Moves & Technical Pattern Recognition Alerts - Bộ Nội Vụ
Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing - TipRanks
Milestone Pharmaceuticals Completes Royalty Interest Sale - TradingView
Will Milestone Pharmaceuticals Inc. stock gain from lower inflationWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Insider Sell: Joseph Oliveto Sells 43,500 Shares of Milestone Ph - GuruFocus
Joseph Oliveto Sells 43,000 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Trend Report: Will Milestone Pharmaceuticals Inc stock gain from government policies2025 Volume Leaders & Safe Capital Growth Tips - Bộ Nội Vụ
How Milestone Pharmaceuticals Inc. stock benefits from global expansion2025 Growth vs Value & Real-Time Market Sentiment Alerts - Улправда
How supply chain issues affect Milestone Pharmaceuticals Inc. stockJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
Will Milestone Pharmaceuticals Inc. stock gain from government policies2025 Sector Review & Risk Managed Investment Strategies - Улправда
Can Milestone Pharmaceuticals Inc. stock continue upward trendJuly 2025 Sentiment & Capital Efficient Trading Techniques - Улправда
Is Milestone Pharmaceuticals Inc. stock a buy in volatile markets2025 Growth vs Value & Short-Term Trading Alerts - Улправда
Milestone announces acceptance of MAA by EMA for etripamil nasal spray - Yahoo Finance
MIST: HC Wainwright & Co. Reiterates Buy Rating with $8 Price Ta - GuruFocus
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Milestone Pharmaceuticals Says EMA Accepts Marketing Application for Etripamil Nasal Spray - marketscreener.com
Milestone’s PSVT nasal spray MAA accepted by EMA - TipRanks
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - The Manila Times
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Travel Stocks: How Milestone Pharmaceuticals Inc stock trades before earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Bộ Nội Vụ
Milestone Pharmaceuticals’ Stock Surges as Cardamyst Receives FDA Approval - StocksToTrade
Milestone Pharmaceuticals (MIST) price target increased by 76.00% to 6.73 - MSN
Wyckoff Accumulation Phase Possible in Aveer Foods LimitedVWAP Trading Strategies & Double Or Triple Profits - earlytimes.in
Milestone Pharmaceuticals (MIST) Price Target Increased by 76.00% to 6.73 - Nasdaq
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen - MarketBeat
Will Milestone Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Earnings & Fast Moving Stock Trade Plans - Улправда
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
자본화:
|
볼륨(24시간):